MARKETS
Markets

Purple Biotech Issued Patent From U.S. Patent And Trademark Office For Its Application Covering Tri-Specific Antibody Constructs, Models

Sep 2, 2026 · 07:32 AM ET· updated 1h ago

Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while

Share
Why It Matters

Purple Biotech got official permission from the U.S. government to use their special cancer-fighting technology—like getting a legal stamp of approval for their invention. This shows their idea is unique and they've done the hard work to protect it, which can help them in the long run.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.